Crizotinib (Xalkori)

These drugs are being tested in clinical trials after surgery or chemoradiation in stage I to 3 lung cancer, but the evidence available so far do not demonstrate that they work in this setting. I do not recommend using these drugs in the curative-intent setting unless as part of a clinical trial.

Xalkori is very successful in causing tumor shrinkage in most patients whose tumors have an ALK fusion. Efficacy is usually measured by tumor shrinkage, time to progression or survival.

The most common side effects of crizotinib (Xalkori) are:
- Gastrointestinal side effects which include nausea, vomiting, decreased appetite, diarrhea, constipation
- Swelling of hands and feets (edema)

Less common side effects include:
- Mild dizziness
- Fatigue
- Insomnia
- Mild rash
- Numbness or tingling
- Cold symptoms
- Arthralgia and back pain


Side effects that are not as common but may present problems are:
- Pneumonitis
- Hepatic liver abnormalities (elevated ALT (alanine aminotransferase) and AST (aspartate aminotransferase) levels
- QT Prolongation which is an irregular heart rhythm

Crizotinib (Xalkori) side effects vary greatly from patient to patient depending on different issues including patient history, existing conditions, other prescribed medications the patient is taking, and stage of disease. Some people experience minimal side effects, while others may experience severe side effects.

If the side effects from Xalkori are severe, you may speak to your physician about medications to treat the side effects. It is important to notify your physician if and when you develop any side effects and to listen to your body and call your healthcare provider if something seems amiss.

Websites that may provide more information include:

http://www.drugs.com/xalkori.html
http://www.pfizerpro.com/hcp/xalkori_home??source=google&HBX_PK=s_+xalkori&HBX_OU=50&o=69985681|245244793|0&skwid=43700003139871797
http://www.rxlist.com/xalkori-drug/side-effects-interactions.htm